Home » News » India » Exclusive | Uzbekistan, Gambia Cough Syrup Cases: 'Concerned' Commerce Ministry Advises Thorough Probe

Exclusive | Uzbekistan, Gambia Cough Syrup Cases: 'Concerned' Commerce Ministry Advises Thorough Probe

An office memorandum written by the export division of the commerce ministry expresses concern over the potential of damaging India’s reputation in the global pharmaceutical export landscape

Advertisement

By: Himani Chandna

Edited By: Pathikrit Sen Gupta

News18.com

Last Updated: January 14, 2023, 07:30 IST

New Delhi, India

The memo said that 'such incidents have the potential of affecting our pharma exports to these countries as well as denting our image as Pharmacy of the World providing quality drugs at an affordable price'. (Representational image/Shutterstock)
The memo said that 'such incidents have the potential of affecting our pharma exports to these countries as well as denting our image as Pharmacy of the World providing quality drugs at an affordable price'. (Representational image/Shutterstock)

The union ministry of commerce and industry has raised “concerns" over the allegations of deaths of children in Uzbekistan and Gambia caused by syrups manufactured by two Indian pharmaceutical firms.

According to an office memorandum written by the export division of the commerce ministry, and accessed by News18.com, “The commerce secretary in a recent review meeting expressed concern about the impact of these incidents on our pharma exports."

It added that the commerce secretary has “emphasised" the need for a “thorough investigation" into the matter and “urgent corrective actions" by the concerned agencies.

The memo, dated January 9, has been sent to the secretary of the ministry of health and family welfare and the secretary of the department of pharmaceuticals.

Advertisement
RELATED NEWS

Titled “recent incidents in Gambia and Uzbekistan related to the death of children due to alleged consumption of Indian drugs" the memorandum expresses concern over the potential of damaging India’s reputation in the global pharmaceutical export landscape.

It said that “such incidents have the potential of affecting our pharma exports to these countries as well as denting our image as ‘Pharmacy of the World’ providing quality drugs at an affordable price".

India has a substantial presence in the pharma markets of both Gambia and Uzbekistan, it says.

‘Seeking update, response awaited’

The letter also points out that the division has been constantly seeking an update on the matter but failed to receive any concrete response.

“Despite our requests to CDSCO and the Department of Health & Family Welfare to provide a status report on the action taken on the matter, the same is awaited," it says.

Advertisement

CDSCO – Central Drugs Standard Control Organisation – is the apex health regulator of India which holds primary responsibility for the regulation of drug manufacturing and selling in the country.

The commerce ministry has requested for all the updates on both the cases – Gambia and Uzbekistan – including the “findings of investigations and the actions proposed to address the quality and regulatory concerns".

“This department may also kindly be kept posted on further developments in both cases," the memo said.

Advertisement

Raid, reproach

Marion Biotech, which is at the centre of a row over the deaths of children in Uzbekistan, was raided by state and central drug controllers on December 27 after Uzbekistan shared the details of the issue with the union health ministry.

Advertisement

On December 30, Pharmexcil— an arm that functions under the ministry of commerce and industry — informed Marion Biotech that these allegations have brought a “bad name" to the entire pharma industry in the global arena and may lead to “trust issues" as well.

Just two months ago, in October, a controversy erupted involving the death of 66 children in the Gambia allegedly after taking cough syrup imported from India.

Read all the Latest India News here

Follow us on

About the Author

Himani ChandnaHimani Chandna writes on healthcare and pharmaceuticals, policy, R&D and cor...Read More

first published: January 14, 2023, 07:30 IST
last updated: January 14, 2023, 07:30 IST